Certuity LLC Acquires Shares of 1,365 Krystal Biotech, Inc. (NASDAQ:KRYS)

Certuity LLC bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 1,365 shares of the company’s stock, valued at approximately $214,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Crossmark Global Holdings Inc. grew its stake in Krystal Biotech by 5.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock valued at $362,000 after buying an additional 121 shares in the last quarter. Perigon Wealth Management LLC raised its stake in shares of Krystal Biotech by 1.5% during the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock valued at $1,200,000 after purchasing an additional 123 shares during the period. KBC Group NV lifted its holdings in Krystal Biotech by 25.9% during the 3rd quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after purchasing an additional 132 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Krystal Biotech by 3.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company’s stock worth $840,000 after purchasing an additional 153 shares during the period. Finally, Pier 88 Investment Partners LLC grew its holdings in Krystal Biotech by 5.1% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 3,530 shares of the company’s stock valued at $643,000 after buying an additional 170 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on KRYS shares. Chardan Capital reissued a “buy” rating and issued a $212.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th. Finally, Citigroup boosted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Krystal Biotech has a consensus rating of “Buy” and an average target price of $206.67.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $155.75 on Friday. Krystal Biotech, Inc. has a 52-week low of $107.50 and a 52-week high of $219.34. The company has a fifty day moving average of $159.73 and a 200-day moving average of $176.66. The company has a market capitalization of $4.48 billion, a P/E ratio of 87.99 and a beta of 0.84.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).